Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 569 results for "Byetta"

Byetta-Drug Insights,2014

Summary 'Byetta - Drug Insights, 2014' provides Byetta marketed details and API Manufacturers details across the globe along with the location. In addition, it covers sales estimates for the US, detailed clinical assessment of the drug, patent ..., 3 weeks ago

Human medicines European public assessment report (EPAR): Byetta, exenatide, Revision: 15, Authorised

This is a summary of the European public assessment report (EPAR) for Byetta. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and ...
 European Medicines Agency1 month ago

Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report

Hundreds of Byetta lawsuits ( and other product liability claims involving a class of Type 2 diabetes drugs known as incretin mimetics continue to move forward in a federal multidistrict litigation now underway in ...
 Digital Journal1 month ago Diabetes Drug Litigation Prepares to Discuss Byetta Lawsuits, Claims over Similar Products at December Conference, Bernstein Liebhard LLP Reports  Digital Journal1 month ago ASTRAZENECA : New Order Issued in Federal Incretin Mimetic Litigation, Where Hundreds of Byetta Lawsuits and other Diabetes Drug Claims Have Been Filed  4 Traders1 month ago New Order Issued in Federal Incretin Mimetic Litigation, Where Hundreds of Byetta Lawsuits and other Diabetes Drug Claims Have Been Filed  Red Orbit1 month ago

exenatide, Byetta

Pharmacy Author: Omudhome Ogbru, PharmD Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University ...
 MedicineNet.com1 month ago Court Report - January 2015 #2  JD Supra3 days ago Court Report - December 2014 #4  JD Supra1 month ago
Jutia Group

Stock Update (NYSE:BMY): U.S. Food and Drug Administration Approves Bristol-Myers Squibb's Evotaz (atazanavir and cobicistat) for the Treatment of HIV-1 Infection in Adults

[Business Wire] Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration has approved Evotaz tablets in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. Read more on this. ...
 Jutia Group10 hours ago Company Update: Bristol-Myers Squibb Company (NYSE:BMY) Merck, Bristol heat up immunotherapy race in lung cancer  Jutia Group2 weeks ago Market Update (NYSE:BMY): Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference  Jutia Group3 weeks ago Market Update: Bristol-Myers Squibb Company (NYSE:BMY) Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2014 on January 27  Jutia Group1 month ago

Test - An Approach to Consider for Type 2 Diabetes Therapy Starts Here

Share this article: Please see Important Safety Information for Trulicity (Dulaglutide) injection 0.75mg and 1.5mg including Boxed Warning about possible thyroid tumors including thyroid cancer below. Please see Prescribing Information ...
 Monthly Prescribing Reference2 days ago

A New Price Estimate Now That Afrezza Is Launching

Summary People report that Afrezza is available at selected pharmacies. Sanofi appears to be launching according to the stated schedule. We have come up with a set of price targets based on historical unit and dollar sales figures for competing ...
 Seeking Alpha3 days ago

Legal-Bay Lawsuit Settlement Funding Announces $6MM Capital Raise for Case Funding in 2015 and Beyond

JERSEY CITY, N.J. , Jan. 26, 2015 /PRNewswire/ --Legal-Bay LLC, The Lawsuit Settlement Funding Company, announced today that they have secured up to $6MM in case funding capital in order to assist plaintiffs with pre-settled and settled case lawsuit ...
 CEOWorld Magazine3 days ago

A Potential Game-Changer in Type 2 Diabetes: GLP-1 Agonist/ Basal Insulin Combinations?

By Emily Regier Twitter summary: The scoop on GLP-1 agonist/basal insulin combos how they work, why were so excited about them, and what's on the horizon Short summary: GLP-1 agonist/basal insulin combinations are some of the most exciting ...
 diaTribe5 days ago

Flamel Technologies Responds To Competition With Significant Bloxiverz Price Increase

Summary Flamel Technologies reacts to surprising FDA news. New price for Bloxiverz should increase revenues. EPS could double. Competitor's Surprise Helps Flamel To Higher Revenues On January 14, 2015, Flamel Technologies (NASDAQ: FLML ) ...
 Seeking Alpha6 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less